26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
24 August 2023REVIVE Webinar – Antimicrobial drug discovery: SAR optimization and QSARThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…read more >>
21 June 2023AMR – Antimicrobial Resistance ConnectDriving innovation, investment, and actionable policy to combat the silent pandemicread more >>
07 June 2023GARDP Webinar: Project management in antimicrobial drug R&DThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
20 March 2023BIO-Europe Spring 2023: Meet your next strategic partner at Europe’s largest springtime partnering event.The annual BIO-Europe Spring® conference will bring together the life science community for global dealmaking in-person and digitally.read more >>
16 March 20237th AMR ConferenceThe AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…read more >>
08 March 2023BioWednesday Cambridge with tranScrip: “Lost in Translation: Smart early clinical development with the end in mind”This BioWednesday event, led by tranScrip will discuss how investors and entrepreneurs evaluate small companies for investment. We will give…read more >>
02 March 2023REVIVE Webinar: Susceptibility testing in antibacterial drug R&DThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
21 February 20235th Bacteriophage Therapy SummitWhether you’re at the forefront of the field or emerging into phage therapy for the first time, the 5th Bacteriophage…read more >>
24 January 2023REVIVE Webinar: Delivery systems in antibacterial drug discoveryThe Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…read more >>
